Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hizofito is a botanical extract derived from *Glycine max* (soybean), developed and marketed by the Brazilian pharmaceutical company Hebron Nutrition. It is standardized to contain soy isoflavones, primarily genistein and daidzein, which function as phytoestrogens. These compounds act as selective estrogen receptor modulators (SERMs), binding to estrogen receptors—with a notably higher affinity for estrogen receptor beta (ER-β)—to provide a mild estrogenic effect. Hizofito is primarily indicated for the relief of vasomotor symptoms associated with menopause (climacteric syndrome), such as hot flashes and night sweats, offering a non-hormonal alternative to traditional hormone replacement therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hizofito.